Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study

Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S2213-2600(18)30151-6
P698PubMed publication ID29773326

P50authorDiana GiannarelliQ44736865
P2093author name stringMichele Maio
Armida D'Incecco
Luana Calabrò
Alessia Covre
Riccardo Danielli
Diana Giannarelli
Aldo Morra
Maresa Altomonte
Anna Maria Di Giacomo
Marlon C Rebelatto
Giovanni Amato
Arthur Lewis
P2860cites workMesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responsesQ40304269
Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patientsQ40554935
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trialQ41008161
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experienceQ41688263
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trialQ44807139
CCR 20th Anniversary Commentary: Immune-Related Response Criteria--Capturing Clinical Activity in Immuno-Oncology.Q45964452
Sample size tables for exact single-stage phase II designsQ47216643
Immune checkpoint inhibitors: new strategies to checkmate cancerQ47400647
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.Q50156159
Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidencesQ56893769
Modified RECIST criteria for assessment of response in malignant pleural mesotheliomaQ61628213
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their InhibitionQ26777563
Improved Survival with Ipilimumab in Patients with Metastatic MelanomaQ27861062
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Q28131668
Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008Q28393456
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaQ29615443
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatmentQ30240296
Clinical applications of PD-L1 bioassays for cancer immunotherapyQ33702815
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trialsQ33845393
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b studyQ33880042
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesotheliomaQ34214330
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivoQ35235365
Immune responses and immunotherapeutic interventions in malignant pleural mesotheliomaQ35711576
Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypesQ37565259
Second line therapy in malignant pleural mesothelioma: A systematic reviewQ38544963
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.Q38669328
PD-1 and PD-L1 antibodies in cancer: current status and future directionsQ38755931
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.Q38909086
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.Q40163076
P433issue6
P407language of work or nameEnglishQ1860
P304page(s)451-460
P577publication date2018-06-01
P1433published inThe Lancet. Respiratory medicineQ27724908
P1476titleTremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study
P478volume6

Reverse relations

cites work (P2860)
Q64250464BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma
Q93048216Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells
Q91123969Checkpoint inhibitors in mesothelioma: hope for the future?
Q90612192Chemotherapy options versus "novel" therapies: how should we treat patients with malignant pleural mesothelioma
Q89598354Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival
Q89881656Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
Q98953063Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in
Q92296725Expression of V-set immunoregulatory receptor in malignant mesothelioma
Q91812276Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting
Q94547635How to select IgG subclasses in developing anti-tumor therapeutic antibodies
Q88720054Immuno-oncology in malignant pleural mesothelioma
Q90612209Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives
Q90179428Immunotherapy in Malignant Pleural Mesothelioma
Q90782085Immunotherapy trials in mesothelioma - promising results, but don't stop here
Q95271900Inducers, Attractors and Modulators of CD4+ Treg Cells in Non-Small-Cell Lung Cancer
Q91123540Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial
Q89622483Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
Q58580151Multimodality treatment of malignant pleural mesothelioma
Q91966584Nivo-lution in Mesothelioma
Q91123974Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
Q61806918Splicing molecular biology and novel therapies in diffuse malignant peritoneal mesothelioma
Q92134624The future of mesothelioma treatment: time to shift gear
Q64981981The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis.
Q91649938Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis

Search more.